Idexx Laboratories, Inc’s filing revealed that its Director SZOSTAK M ANNE unloaded Company’s shares for reported $0.65 million on May 21 ’25. In the deal valued at $512.34 per share,1,260 shares were sold. As a result of this transaction, SZOSTAK M ANNE now holds 1,801 shares worth roughly $0.95 million.
Then, SZOSTAK M ANNE sold 1,046 shares, generating $537,372 in total proceeds. Upon selling the shares at $513.74, the Director now owns 262 shares.
Before that, SZOSTAK M ANNE bought 1,260 shares. Idexx Laboratories, Inc shares valued at $651,621 were divested by the Director at a price of $517.16 per share.
Leerink Partners initiated its Idexx Laboratories, Inc [IDXX] rating to an Outperform in a research note published on December 02, 2024; the price target was $500. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Piper Sandler also remained covering IDXX and has decreased its forecast on January 30, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. Exane BNP Paribas started covering the stock on December 07, 2023. It rated IDXX as “an Outperform”.
Price Performance Review of IDXX
On Tuesday, Idexx Laboratories, Inc [NASDAQ:IDXX] saw its stock jump 1.41% to $525.93. Over the last five days, the stock has gained 0.02%. Idexx Laboratories, Inc shares have risen nearly 27.21% since the year began. Nevertheless, the stocks have risen 5.64% over the past one year.
How much short interest is there in Idexx Laboratories, Inc?
A steep rise in short interest was recorded in Idexx Laboratories, Inc stocks on 2025-05-30, dropping by -0.3 million shares to a total of 2.57 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 2.87 million shares. There was a decline of -11.6%, which implies that there is a negative sentiment for the stock.
